Somewhat Favorable News Coverage Somewhat Unlikely to Impact Baxalta (BXLT) Stock Price
Media coverage about Baxalta (NYSE:BXLT) has trended somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Baxalta earned a news impact score of 0.09 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 46.147990837705 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Baxalta (BXLT) traded down 0.39% during mid-day trading on Wednesday, hitting $46.02. The stock had a trading volume of 228,648,358 shares. The company has a 50 day moving average price of $46.02 and a 200 day moving average price of $46.02. Baxalta has a one year low of $37.44 and a one year high of $46.52.
Baxalta Company Profile
Baxalta Incorporated (Baxalta) is a biopharmaceutical company with a portfolio of differentiated therapies that seek to address medical needs across various disease areas, including hemophilia, immunology and oncology. Baxalta’s categories of products include Hemophilia products, such as Advate, Adynovate, Recombinate, Hemofil M, Immunate, Immunine, Rixubis and Prothromplex Total; Inhibitor Therapies products, including FEIBA and OBIZUR; Immunoglobulin Therapies products, which include GAMMAGARD LIQUID/KIOVIG, HYQVIA, GAMMAGARD S/D and SUBCUVIA; BioTherapeutics products, including FLEXBUMIN, BUMINATE, ARALAST NP, GLASSIA NP and CEPROTIN, and Oncology product, such as ONCASPAR.
Receive News & Stock Ratings for Baxalta Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxalta Inc and related stocks with our FREE daily email newsletter.